Perineural Invasion – Is It An Accurate Predictor of Extra-Prostatic Extension of Prostate Cancer?

Many clinicians are concerned when a patient comes to them with prostate cancer that has been shown to have perineural invasion (PNI). PNI is defined as the presence of prostate cancer found by biopsy that tracks along or around a nerve within the perineural space. The presence of PNI has been a concern because of [...]

Metastasis-Free Survival Is A Possible Biomarker for Overall Survival

Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases. Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint [...]

Commonly Used FDA Approved Treatments for Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The first line of treatment for advanced prostate cancer is Androgen (male hormone) Deprivation Therapy or ADT. Once the PSA progresses (climbs) while still on ADT and with testosterone levels

Cleveland Clinic Identifies Genetic Mutation in a Deadly form of Prostate Cancer

Dr. Nima Sharifi from the Cleveland Clinic’s Lerner Research Institute has claimed to have identified a genetic mutation in one of the deadliest forms of prostate cancer. His finding, published online today in the journal Cell, shows that there is a mutation that occurs in an enzyme that is present in a drug resistant form [...]

Evidence Against Step Therapy Being Good for Prostate Cancer Care

On August 13, 2013 I wrote an important post about the terrible practice beginning to rear its head called step therapy. Step therapy is the practice of insurance companies requiring less expensive drugs be prescribed prior to more expensive ones despite the comparative efficacy of the drugs and their different mechanisms of action. This practice [...]

Go to Top